RT Journal Article
SR Electronic
T1 Endothelial Extracellular Vesicles Enriched in microRNA-34a Predict New-Onset Diabetes in Coronavirus Disease 2019 (COVID-19) Patients: Novel Insights for Long COVID Metabolic Sequelae
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 34
OP 39
DO 10.1124/jpet.122.001253
VO 389
IS 1
A1 Mone, Pasquale
A1 Jankauskas, Stanislovas S.
A1 Manzi, Maria Virginia
A1 Gambardella, Jessica
A1 Coppola, Antonietta
A1 Kansakar, Urna
A1 Izzo, Raffaele
A1 Fiorentino, Giuseppe
A1 Lombardi, Angela
A1 Varzideh, Fahimeh
A1 Sorriento, Daniela
A1 Trimarco, Bruno
A1 Santulli, Gaetano
YR 2024
UL http://jpet.aspetjournals.org/content/389/1/34.abstract
AB Emerging evidence indicates that the relationship between coronavirus disease 2019 (COVID-19) and diabetes is 2-fold: 1) it is known that the presence of diabetes and other metabolic alterations poses a considerably high risk to develop a severe COVID-19; 2) patients who survived a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have an increased risk of developing new-onset diabetes. However, the mechanisms underlying this association are mostly unknown, and there are no reliable biomarkers to predict the development of new-onset diabetes. In the present study, we demonstrate that a specific microRNA (miR-34a) contained in circulating extracellular vesicles released by endothelial cells reliably predicts the risk of developing new-onset diabetes in COVID-19. This association was independent of age, sex, body mass index (BMI), hypertension, dyslipidemia, smoking status, and D-dimer.SIGNIFICANCE STATEMENT We demonstrate for the first time that a specific microRNA (miR-34a) contained in circulating extracellular vesicles released by endothelial cells is able to reliably predict the risk of developing diabetes after having contracted coronavirus disease 2019 (COVID-19). This association was independent of age, sex, body mass index (BMI), hypertension, dyslipidemia, smoking status, and D-dimer. Our findings are also relevant when considering the emerging importance of post-acute sequelae of COVID-19, with systemic manifestations observed even months after viral negativization (long COVID).